The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q4 2022 call → NO我们根据要求,需要判断是否有一个明确的、公司特定的疑虑,并且当前期间的实际运营证据是否反驳了该疑虑。从电话会议中,我们看到分析师和公司管理层讨论了多个话题,如新泳池建设下降、通货膨胀、供应链正常化、市场份额等。但我们需要找到一个“standing doubt”——一个长期存在的、公司特定的担忧,并且当前证据与之相反。 可能的疑虑:新泳池建设下降?但这是行业性的,不是公司特定的。或者关于毛利率下降?但那是预期中的。或者关于欧洲业务?但那是区域性的。或者关于Horizon业务?但管理层表示其表现良好。或者关于化学产品进口关税?但那是非经常性的。 仔细阅读,分析师多次询问关于新泳池建设、市场份额、毛利率等,但似乎没有明显的“standing doubt”被反复提及。管理层在回答中提到了“我们相信2023年将是坚实的一年”,但这是展望。当前期间的实际证据:第四季度收入增长6%,全年增长17%,毛利率全年增长80个基点,但第四季度毛利率下降230个基点(部分由于关税)。管理层提到“我们继续获得市场份额”,但这是陈述而非具体证据。 也许疑虑是关于“新泳池建设下降”是否会影响公司?但管理层给出了具体数字:2022年新泳池建设约98,000个,下降16%,而公司的新建业务下降12-13%,表明公司表现优于行业。这可能是反驳。但这是否是“standing doubt”?分析师可能担心新泳池建设下降会拖累公司,但管理层用实际数据表明公司份额增加。 另一个可能的疑虑:关于供应链正常化后,客户购买习惯改变,是否会影响销售?管理层提到第四季度零售客户发货增长1%,但全年增长9%,并解释这是正常化。但这不是长期疑虑。 或者关于毛利率的可持续性?管理层解释毛利率下降是价格成本回吐,但全年仍增长。 我认为最接近的是:分析师可能担心新泳池建设下降会严重影响公司,但管理层用实际数据(公司新建业务下降幅度小于行业)来反驳。但这是否是“standing doubt”?在电话会议中,分析师多次询问新泳池建设,但管理层给出了预期和实际数据。然而,这更多是行业趋势,而非公司特定疑虑。 另一个可能:关于欧洲业务下滑,管理层承认欧洲销售下降22.5%,但表示长期增长机会。这似乎是确认疑虑而非反驳。 或者关于Horizon业务?管理层表示其表现良好,但分析师没有特别质疑。 也许疑虑是关于公司能否维持高增长?但管理层给出了2023年指引,但那是展望。 再读一遍,分析师Ryan Merkel问“volume assumption”,管理层详细解释。分析师David Manthey问“pre-buy”水平,管理层回答。分析师Susan Maklari问竞争动态,管理层回答。分析师Andrew Carter问关税和SG&A,管理层回答。分析师Joe Ahlersmeyer问第一季度销售和毛利率,管理层回答。分析师Noah问维护业务,管理层回答。分析师Joseph问自由现金流,管理层回答。分析师Shaun问市场份额,管理层回答。分析师Jeffrey问三氯价格,管理层回答。 似乎没有一个明确的、反复出现的公司特定疑虑。所有问题都是关于当前业绩和未来展望,但管理层都给出了具体数据和解释。没有迹象表明有一个长期存在的疑虑被反复提及。 也许疑虑是关于“新泳池建设下降”是否会导致公司收入下降?但管理层给出了具体数据表明公司表现优于行业。但这是否是“standing doubt”?在电话会议中,分析师没有明确说“我们担心新泳池建设下降”,而是直接问假设。管理层也给出了预期。 另一个可能:关于毛利率下降,分析师问“毛利率下降原因”,管理层解释。但这不是长期疑虑。 我认为没有明确的“standing doubt”。因此答案应为NO。 但让我们再仔细看:管理层在开头说“2022年又是非凡的一年”,然后提到“我们继续扩大市场份额”。分析师问“竞争动态”,管理层回答。分析师问“新泳池建设”,管理层给出数据。似乎没有分析师表达担忧,而是询问细节。 也许疑虑是关于“公司能否在供应链正常化后保持增长”?但管理层用实际数据表明第四季度仍增长6%。 或者疑虑是关于“化学产品进口关税”的影响?但那是非经常性的。 我认为没有符合要求的疑虑。因此答案NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.